Engineering Circular RNA for Sustained Expression in Precision Oncology
By joining the ends of the RNA strand into a loop, researchers are evaluating circular RNA to resist degradation and extend protein expression in cancer applications.
Key takeaways
- Circular RNA's closed-loop topology lacks free ends, conferring resistance to exonuclease degradation and enabling sustained protein expression for days to weeks.
- Engineered circRNA utilizes cap-independent translation methods, such as IRES and m 6 A-driven pathways, to initiate protein synthesis.
- Recent advances include rolling-circle translation for multi-epitope vaccine design and programmable stability circuits that integrate tumor-microenvironment cues like miRNA signatures.
- Key applications include cancer vaccines, transient CAR-T/NK cell engineering, tumor-suppressor replacement, and bispecific T-cell engagers.
- Clinical translation is currently limited by manufacturing bottlenecks, process scalability, and the need for pharmacokinetic tracking and specific regulatory pathways.
Linear messenger RNA (mRNA) molecules have an inherent vulnerability: they degrade quickly. Because linear strands have exposed ends, cellular enzymes can easily latch onto and break them down, limiting the duration of their therapeutic effects. To address this limitation, researchers are evaluating a different molecular geometry: circular RNA, or circRNA. By joining the ends of the RNA strand into a continuous loop, the molecule is shielded from degradation.
According to a review published in the journal Biotechnology and bioengineering in August 2026, circular RNA's topology lacks free ends, which confers resistance to exonuclease degradation and enables sustained protein expression for days to weeks. The review suggests that circular topology should be viewed as an active pharmacologic variable rather than merely a stability enhancement.
What Happened
The review highlights several technological advances that make engineered circRNA viable. Because circular RNA lacks the traditional structures found in linear mRNA, scientists are evaluating alternative pathways, including internal ribosome entry sites (IRES) elements and m 6 A-driven mechanisms, to initiate translation.
Additionally, the review highlights recent advances in rolling-circle translation for multi-epitope vaccine design, as well as programmable stability circuits that integrate tumor-microenvironment cues such as miRNA signatures. Beyond engineered therapeutics, endogenous circular RNAs exhibit cancer-associated expression patterns and persist in biofluids, serving as candidate biomarkers for diagnosis and longitudinal disease monitoring.
What The Evidence Shows
The review, published in Biotechnology and bioengineering in August 2026, synthesized recent research on RNA topology, translation, and delivery systems. The evidence indicates that circular RNA's topology lacks free ends, conferring resistance to exonuclease degradation and enabling sustained protein expression for days to weeks.
The analysis also highlights advances in selective delivery, including antibody-guided lipid nanoparticles and engineered extracellular vesicles, which enable selective RNA delivery. Additionally, local depot formulations and organ-selective systemic routes expand therapeutic reach. Key potential applications for the technology include circRNA cancer vaccines, transient CAR-T/NK cell engineering, tumor-suppressor replacement, and circRNA-encoded bispecific T-cell engagers.
What We Don't Know Yet
Translating circular RNA into clinical applications presents several challenges. Clinical-scale recovery and process scalability remain insufficiently characterized. In addition, safety considerations remain complex: innate immunogenicity can serve as a self-adjuvant for cancer vaccines, whereas back-splice-junction neoantigens offer both vaccine opportunities and tolerance risks.
What Comes Next
To translate circular RNA from laboratory research to clinical applications, the field requires real-time pharmacokinetic tracking, reproducible and scalable manufacturing, validated liquid-biopsy assays, and indication-specific regulatory pathways.
Recent advances in scarless circularization, topology-sensitive purification, dsRNA depletion, and lyophilized formulations have begun to address some manufacturing bottlenecks, but scalability is not yet fully characterized.
What This Means
For precision oncology, circular RNA represents a potential shift toward writing highly durable, programmable cellular instructions. If the technology successfully transitions to clinical practice, researchers could deploy programmable stability circuits that integrate tumor-microenvironment cues such as miRNA signatures.
Original Source
PubMed (NCBI E-utilities): https://pubmed.ncbi.nlm.nih.gov/42590828/
Questions readers ask
- Why is circular RNA more stable than linear mRNA?
- Circular RNA lacks free ends, which makes it highly resistant to exonuclease degradation. This unique closed-loop topology enables sustained protein expression for days to weeks.
- What are programmable stability circuits in circRNA?
- Programmable stability circuits are recent engineering advances in circular RNA that integrate tumor-microenvironment cues, such as microRNA (miRNA) signatures, to influence how the RNA behaves within specific tissues.
- What challenges must be overcome before circular RNA can be used in clinics?
- Translating circular RNA to clinical applications requires resolving manufacturing bottlenecks, characterizing clinical-scale recovery and process scalability, developing real-time pharmacokinetic tracking, and establishing indication-specific regulatory pathways.
What this means
Circular RNA represents a potential shift in precision oncology toward more durable therapeutics. If the technology successfully transitions to clinical practice, researchers could deploy programmable stability circuits that integrate tumor-microenvironment cues such as miRNA signatures.
Limitations and uncertainties
- The therapeutic potential of circular RNA is currently limited by manufacturing bottlenecks, as clinical-scale recovery and process scalability remain insufficiently characterized. Additionally, potential safety and immunological issues, such as the tolerance risks associated with back-splice-junction neoantigens, require further investigation.
Sources
- Circular Logic: Engineering Next-Generation Circular RNA Therapeutics for Precision Oncology. — PubMed (NCBI E-utilities)
